Recombinant staphylokinase-hirudin fusion protein

注射用重组葡激酶-水蛭素融合蛋白

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant staphylokinase-hirudin fusion protein
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionUrokinase plasminogen activator stimulantsProthrombin inhibitorsPlasminogen metabolizers
TargetsPlasminogenProthrombinUrokinase plasminogen activator
Therapy Area/IndicationsThromboembolism
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (IND)
Highest Status in ChinaPending
Originator CompaniesInstitute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical SciencesHumanwell Healthcare (Group) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesWuhan Optical Valley Humanwell Biological Pharmaceutical Co LtdInstitute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences
Active IndicationsN/A
Inactive IndicationsThromboembolism

Other Information

ATC CodeN/A
Related LinksN/A